Article

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

2021-01-20

Abstract excerpt

Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative, breast cancer patients. However, the value of this combination in potentially curable earlier stage patients is not clear. Using single cell transcriptomic profiling, we examined the evolutionary trajectories of early stage breast cancer tumors using serial tum...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 80060708-185b-5c89-b4d8-6422238acc13
DOI: 10.1101/2021.01.19.427299

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsDOI 10.1101/2021.01.19.427299Read

Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitorsSemantic proximity Read

Chemotherapy reshapes cellular clonal landscape via persister programs in breast cancer xenograftsSemantic proximity Read

Single-cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancersSemantic proximity Read

Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistanceSemantic proximity Read

Combating subclonal evolution of resistant cancer phenotypes.Semantic proximity Read

A Multimodal Framework to Uncover Drug-Responsive Subpopulations in Triple-Negative Breast CancerSemantic proximity Read

Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase InhibitionSemantic proximity Read

Subclonal heterogeneity and evolution in breast cancerSemantic proximity Read

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read

Single cell decoding of drug induced transcriptomic reprogramming in triple negative breast cancersSemantic proximity Read

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapySemantic proximity Read

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerSemantic proximity Read